|
AU2004203394A1
|
|
Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof
|
|
AU2003235032A1
|
|
Pressurized metered dose inhalers and pharmaceutical aerosol formulations
|
|
AU3558402A
|
|
Method and compositions for administering taxanes orally to human patients
|
|
AU1543002A
|
|
Soluble prodrugs of paclitaxel
|
|
AU9749101A
|
|
Method and compositions for treating impotence
|
|
ZA200103375B
|
|
Methods and compositions for the prevention of tolerance to medications.
|
|
WO0172300A1
|
|
Uses of metal salts to stabilize taxane-based compositions
|
|
AU3906801A
|
|
Process for manufacturing paclitaxel and 13-acetyl-9-dihydrobaccatin iii
|
|
AU3285801A
|
|
Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof
|
|
AU1104201A
|
|
Method and compositions for administering taxanes orally to human patients
|
|
US6395770B1
|
|
Method and compositions for administering taxanes orally to human patients
|
|
AU4236599A
|
|
Compositions for treatment of insulin resistance syndromes
|
|
US6235725B1
|
|
Methods and compositions for the prevention of tolerance to medications
|
|
CZ20004793A3
|
|
Pressure inhalators with metered dosages and pharmaceutical aerosol preparations
|
|
AU3395999A
|
|
Method and compositions for treating impotence
|
|
CZ20004271A3
|
|
Preparations containing organic mononitrates or dinitrates, suitable for treating impotence
|
|
US6290930B1
|
|
Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
|
|
US6004537A
|
|
Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
|
|
US6187745B1
|
|
Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
|
|
CZ2000426A3
|
|
Pharmaceutical preparation intended for treating late phase of allergic reaction and inflammatory disease
|
